By Paige Minemyer
Horizon Blue Cross Blue Shield of New Jersey has filed suit against Regeneron Pharmaceuticals charging the company has paid "kickbacks" to a charity in order to boost sales of its Eylea drug.
read more
By Andrea Park
The system was initially granted the FDA’s emergency OK within the first few months of the COVID pandemic.
read more
By Angus Liu
For decades, the FDA has been offering accelerated approvals to open early access to new cancer drugs, but mostly for patients who've already tried several other regimens. FDA oncology chief Richard Pazdur, M.D., now plans to disrupt that longstanding practice and bring quick approvals to early treatment.
read more
By Kevin Dunleavy
Less than three years after launching a budding blockbuster in breast cancer drug Piqray (alpelisib), Novartis has scored an approval to treat PIK3CA-related overgrowth spectrum (PROS), a rare condition that causes blood vessel abnormalities and overgrowth of tissue that can present in a variety of ways.
read more
By Eric Sagonowsky
Looking to bolster Sanofi's portfolio of marketed drugs and pipeline prospects, CEO Paul Hudson went on a dealmaking spree last year. That included the drugmaker's $1.9 billion buyout of Kadmon, where more than two dozen staffers are now losing their jobs.
read more
By Gabrielle Masson
Gilead has unveiled a new global pediatric drug development center in Ireland, which will have 33 job openings by the end of 2022.
read more
By Natalie Missakian
The Trump administration used taxpayer money to pay a contractor with ties to a senior health department official to plan a star-studded COVID-19 ad campaign before the 2020 election, and initially vetted the participating celebrities based on their politics, a new report by the Government Accountability Office confirms.
read more
By Paige Minemyer
UnitedHealth Group's Optum and Change Healthcare have further extended their merger agreement to Dec. 31. The extension comes ahead of a two-week trial to determine the deal's fate.
read more
By Annalee Armstrong
Genentech has been working on gantenerumab for 20 years, and, while it's tempting to try to rush the clinical process, the Roche unit is slowly but surely following the evidence.
read more
By Conor Hale
TARA’s “heart-on-a-chip” system creates a small, working simulacrum of the beating organ to help researchers predict the success of potential therapies.
read more
By Dave Muoio
The White House's long COVID directives include targeted education for providers, further exploration of health insurance coverage, disability protections and more.
read more
By Andrea Park
This summer, Boston Scientific will lose one of its longest-serving executives as David Pierce heads into retirement after spending his entire career with the medtech giant.
read more
By Ben Adams
Patients with common but deeply uncomfortable gastrointestinal issues are still struggling to manage their conditions. A Salix-sponsored survey found patients with IBS or chronic constipation saw symptoms worsen—and for some of them, begin—during the pandemic.
read more
